(Jan 12): Moderna Inc said its US Covid-19 business did better than expected last year, a rare bright spot for the vaccine maker, which has struggled with the decline of people getting its shot. The number of people in the US getting Covid-19 shots fell 26% in 2025, according to chief financial officer Jamey Mock. The company expects potential approvals for its flu vaccine in several countries this year. But it doesn’t anticipate its flu shot will be widely available in the US until 2027, Mock said. For months, Moderna has been seeking a financial partner to fund some late-stage vaccine trials.

Source: The Edge Markets January 12, 2026 12:43 UTC